Chief Financial Officer · Cue Biopharma, Inc. (CUE)

Kerri-Ann Millar

A named executive officer of Cue Biopharma in every fiscal year CompBrief holds from FY2019 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,162,538

Salary $444,181Stock awards $0

FY2022: $1,056,924

3rd of 3 named executive officers at Cue Biopharma by FY2023 total.

3 named officers on file for Cue Biopharma, FY2023

Kerri-Ann Millar’s pay file — $29

  • 5 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Cue Biopharma’s whole pay program stands against its peers

  • Cue Biopharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CUE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A).

Free

Get Kerri-Ann Millar’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Kerri-Ann Millar compensation by year

Cue Biopharma Summary Compensation Table · all 5 fiscal years held
In US dollars, as Cue Biopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022FY2023
Salary$215,000$292,500$374,231$418,459$444,181
Bonus$82,775$108,063$118,125$137,000$0
Stock awards$0$397,400$0$0$0
Option awards$146,454$1,392,578$861,455$497,890$715,201
Non-equity incentive$0$0$0$0$0
Pension and deferred compensation$0$0$0$0$0
All other$4,092$4,092$4,200$3,576$3,156
Total$448,321$2,194,633$1,358,011$1,056,924$1,162,538

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cue Biopharma, Inc. DEF 14A filed April 26, 2024, accession 0000950170-24-049072, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Cue Biopharma, Inc. filed document, accession 0000950170-24-049072. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

$448K
$2.2M
$1.4M
$1.1M
$1.2M
FY19
FY20
FY21
FY22
FY23
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option89,459—$4.20
Option3,750—$16.26
Option16,250—$19.87
Option26,250—$15.55
Option53,125—$6.91
Option6,250—$5.01
Option108,500—$3.21

Per the Outstanding Equity Awards at Fiscal Year-End table in Cue Biopharma, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Cue Biopharma’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Daniel PasseriChief Executive Officer$3,015,480
Anish SuriPresident and Chief Scientific Officer$1,242,468
Kerri-Ann Millar · this pageChief Financial Officer$1,162,538

The full Cue Biopharma compensation record

free company brief

This page is one person within Cue Biopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cue Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kerri-Ann Millar's compensation dossier · One-time report. No refunds.